New adhd drug
Pro Research Analysisby 
Searched over 200M research papers
New ADHD Drug Developments
Introduction to ADHD and Current Treatments
Attention-deficit/hyperactivity disorder (ADHD) is a prevalent neurodevelopmental disorder characterized by inattention, hyperactivity, and impulsivity. It affects approximately 5% of children and 2.5% of adults globally6. The primary pharmacological treatments for ADHD include central nervous system stimulants like methylphenidate and amphetamines, as well as non-stimulants such as atomoxetine and guanfacine2 6.
Methylphenidate: Efficacy and Safety
Methylphenidate is one of the most commonly prescribed medications for ADHD. It has been shown to improve ADHD symptoms and general behavior in children and adolescents, although the certainty of the evidence is very low due to high risk of bias in the studies1 8. Extended-release formulations of methylphenidate have also been studied in adults, showing small-to-moderate improvements in ADHD symptoms but with an increased risk of adverse events4. Common non-serious adverse events include sleep problems and decreased appetite1 8.
Atomoxetine: An Alternative to Stimulants
Atomoxetine, a selective norepinephrine reuptake inhibitor, is another treatment option for ADHD. Studies have shown that atomoxetine has comparable therapeutic effects to methylphenidate in children, with similar safety and tolerability profiles5. This makes it a viable alternative for patients who may not respond well to stimulant medications.
Emerging Non-Stimulant Medications
Recent research has focused on developing novel non-stimulant medications for ADHD. Some of the promising candidates include viloxazine, dasotraline, and centanafadine, which target various biological pathways7 10. These new drugs aim to offer better tolerability and efficacy, particularly for patients who do not respond well to existing treatments.
Trends in ADHD Treatment Research
The landscape of ADHD treatment is evolving, with a significant increase in clinical trials exploring both pharmacological and non-pharmacological therapies. Approximately 80% of recent studies have focused on non-pharmacological interventions, such as behavioral therapies, physical activity, and complementary methods like meditation and hypnotherapy2. This trend highlights the growing interest in holistic and individualized treatment approaches.
Conclusion
The treatment of ADHD continues to advance with ongoing research into both existing and novel medications. While methylphenidate remains a cornerstone of ADHD treatment, alternatives like atomoxetine and emerging non-stimulant drugs offer promising options for patients. The future of ADHD treatment lies in a multimodal approach that combines pharmacological and non-pharmacological therapies to address the diverse needs of patients.
Sources and full results
Most relevant research papers on this topic
Methylphenidate for children and adolescents with attention deficit hyperactivity disorder (ADHD).
Methylphenidate may provide benefits for children and adolescents with ADHD, but its long-term safety and effectiveness remain uncertain.
Systematic Review
Highly CitedTreatment of ADHD: Drugs, psychological therapies, devices, complementary and alternative methods as well as the trends in clinical trials
ADHD treatment primarily involves non-pharmacological therapies, with pharmacological treatments accounting for 20% of all studies.
Systematic ReviewAn updated safety review of the current drugs for managing ADHD in children
ADHD medications in children and adolescents show favorable efficacy, safety, and tolerability, but some may not tolerate them or achieve satisfactory improvement.
Systematic ReviewExtended-release methylphenidate for attention deficit hyperactivity disorder (ADHD) in adults.
Extended-release methylphenidate may provide benefits for adults with ADHD, but more rigorous research is needed to confirm these findings.
Meta-Analysis
Very Rigorous JournalAtomoxetine and methylphenidate treatment in children with ADHD: a prospective, randomized, open-label trial.
Atomoxetine and methylphenidate both show similar therapeutic effects and safety in children with ADHD, with no statistically significant differences observed.
RCTHighly CitedEvidence-based pharmacological treatment options for ADHD in children and adolescents.
Pharmacological treatment options for ADHD in children and adolescents show large effect sizes and good tolerability, but more research and novel medications are needed for improved outcomes.
Systematic ReviewHighly CitedBeyond stimulants: a systematic review of randomised controlled trials assessing novel compounds for ADHD
Novel non-stimulant ADHD medications may offer comparable or better tolerability than stimulants, advancing precision medicine in ADHD treatment.
Systematic ReviewMethylphenidate for children and adolescents with attention deficit hyperactivity disorder (ADHD).
Methylphenidate is a widely used treatment for children and adolescents with ADHD, providing benefits such as improved attention and reduced hyperactivity, but also posing potential harms.
Systematic ReviewVery Rigorous JournalHighly CitedENTRY IN THE ADHD DRUGS MARKET: WELFARE IMPACT OF GENERICS AND ME-TOO'S
New ADHD drugs significantly improve welfare by reducing substitute drug prices and providing alternative delivery mechanisms, suggesting that follow-on patented drugs may benefit from unanticipated innovations like delivery mechanisms.
Observational StudyEmerging drugs for the treatment of attention-deficit hyperactivity disorder (ADHD)
Emerging drugs like amantadine and tipepidine show promise as add-on treatments for ADHD, while viloxazine and dasotraline show promise as stand-alone treatments.
Literature Review